



Q ENHANCED BY Google

BLOG | SYNGENE | CONTACT US Quick li

ABOUT US

OUR BUSINESS

R & D

TECHNOLOGY

INVESTORS

MEDIA

CAREERS

CS



> ABOUT US

Overview

Fact Sheet

Vision Mission Values

People

Quality

CSR Policy

EHS Policy

History

Awards

Biocon Malaysia

History

Biocon evolved from manufacturing speciality enzymes to pharmaceuticals like statins and immunosuppressants, to discovering, developing, and producing life-saving biotherapeutics. It has been a journey of endurance over several decades - from being the 'first Indian company' to win U.S. Food & Drugs Administration (FDA) approval for manufacturing Lovastatin API in 2001, to becoming the 'first' company globally to get its Biosimilars approved and commercialized in the U.S., EU, Japan, and other developed markets. In this long and eventful journey, we have pushed many challenging boundaries and emerged as India's premier biopharmaceutical enterprise.

November 29, 1978

Biocon's Founding Day - the start of a biorevolution in India. Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated biopharmaceutical enterprise. Today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs.

Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw

1979

Biocon is the first Indian company to manufacture and export enzymes to USA and Europe

1989

Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International

Biocon is the first Indian biotech company to receive US funding for proprietary technologies

1990

Biocon scales up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level



1993

Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany

1994

Biocon establishes Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector

1996

The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion

Biocon leverages its technology platform to enter biopharmaceuticals and statins

1997

Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility

1998

Unilever inks a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity

2000

Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals

Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development

2001

Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule

Biocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and world-wide patent

2002

Clinigene's clinical laboratory is the first in India to receive CAP accreditation

2003

Biocon is the first company worldwide to develop human insulin on a Pichia expression system

2004

Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of \$1.11 billion, making Biocon only the second Indian company to cross the \$1 billion mark on the first day of listing.

Syngene establishes new research centre

Biocon Limited, announced the launch of INSUGEN®, the new generation bio-insulin, manufactured in Asia's largest human insulin plant.

Biocon Limited and Vaccinex, Inc. announce a broad strategic partnership to discover and co-develop at least four therapeutic antibody products.

2005

Biocon signs a commercial agreement for supply of insulin API to Asia, Africa and the Middle East.

2006

Biocon inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park

Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate.

Biocon announced a licensing agreement with Bayer HealthCare (BHC) for the exclusive marketing and trademark rights for INSUGEN® for the Chinese market.

Syngene and Innate Pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease.

Biocon launches India's first anti-cancer drug BIOMAb EGFR®.

2007

Biocon and Abu Dhabi based pharmaceutical company Neopharma sign an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).

Biocon grants exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR® in Pakistan.

Biocon announced the launch of its Nephrology Division and a comprehensive portfolio of renal therapy products.

Syngene enters into a research partnership with Bristol-Myers Squibb and completes the ground breaking ceremony of new research facility at Biocon Park.

Biocon signs Memorandum of Understanding with Deakin University, Australia. To establish Deakin Research Institute in Bangalore

Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on biopharmaceuticals

Biocon and Abraxis BioScience, announce an agreement wherein

Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union.

Biocon and Neopharma sign an MoU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.

Biocon presents the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam.

2008

Biocon acquires a 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million

Biocon launches a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe™ and NUFIL Safe™ are the first two drugs that will marketed using this novel device with other injectable products to follow in the future.

Biocon is ranked among the top 20 global biotechnology companies (Med Ad News).

Biocon is the 7th largest biotech employer in the world (Med Ad News).

Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome.

2009

Biocon's Syngene partners with Sapient Discovery to expand integrated drug discovery offerings

Biocon's Syngene and DuPont Crop Protection Forge Alliance Partnership

Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park

Biocon launches BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics

Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management

Biocon announced Strategic Collaboration with Mylan to enter the Global Generic Biologics Market

Biocon Limited and Amylin Pharmaceuticals entered into a Global Development and Commercialization Agreement for a Novel Peptide Hybrid. The Program will focus on the potential treatment of diabetes.

Biocon and HCG group of hospitals join hands to fight against cervical

2010

Biocon explores investment in Malaysia in partnership with BiotechCorp

Biocon and Bayer join hands to create awareness for self monitoring for diabetics

Syngene and Endo Pharmaceuticals, USA to jointly discover and develop novel biological drug molecules to fight cancer

Biocon acquires stake of its Cuban partner CIMAB S.A. in their seven year old JV, Biocon Biopharmaceuticals Pvt. Ltd

Biocon and Optimer Pharmaceuticals announce manufacturing and supply agreement for a novel API, first-in-class anti-infective (C. difficile)

Biocon and the Center of Molecular Immunology (CIM), based in Havana, Cuba strengthen their existing research partnership by joining forces for an integrated antibody program in immunology

Biocon announced a strategic foreign direct investment in Malaysia with the Malaysian Biotechnology Corporation SdnBhd (BiotechCorp)

2011

Biocon divests its stake in its German subsidiary, AxiCorp GmbH, to the existing group of promoter shareholders, AxiCorp was the licensee for Biocon's biosimilar Insulin and Glargine in Germany and had the sole responsibility for commercializing these products. As a consequence of this divestment, these rights revert to Biocon.

Biocon announced project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia

Biocon launches INSUPen[®], a convenient and affordable reusable insulin delivery device

2012

Biocon announced Positive Results from its Global Phase 3 study with Recombinant Human Insulin

GE Capital invests in Syngene, Biocon's Research Services Subsidiary

Biocon announced Positive Efficacy Data from Phase 3 clinical study with its Novel Monoclonal Antibody, Itolizumab for Psoriasis

Syngene - a subsidiary of Biocon Group, in collaboration with Abbott, setup a dedicated Nutrition Research and Development Center at Biocon Park

Biocon announced positive results from its Phase 1 Comparative PK-PD Study with Biosimilar Insulin Glargine

Biocon: the only Asian Company to Feature in the Global Top 20 BioPharma Employers, by Science Magazine

Biocon enters into an agreement with Bristol-Myers Squibb for its IN-105, an Oral Insulin drug

2013

Biocon received Marketing Authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis

Biocon enhances Partnership with Mylan through Strategic Collaboration for Insulin Products

Biocon Delivers a Healthy Growth of 22% driven by strong traction

in Biopharma

Biocon Launched ALZUMAb™ - a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India

Biocon Partnered with CytoSorbents to Market CytoSorb® - A 'First-in-Class' Therapy for Sepsis Management

Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the Science Magazine

Biocon Unveils Biocon Academy - A Center of Excellence for Advanced Learning in Applied Biosciences

Biocon & Mylan received Indian Regulatory Approval for Trastuzumab for Treating Breast Cancer

Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics

Biocon's ALZUMAB™ wins BioSpectrum BioPharma Product of the Year, 2013

Biocon Academy's Flagship Program in Collaboration with KGI Takes Off to a Flying Start

2014

Biocon has been conferred with the Sir J C Bose Memorial Award – 2013 (Institutional category) by Indian Science Monitor (ISM) for its contribution in the field of Biotechnology, with special reference to the launch of ALZUMAb (Itolizumab)

Biocon introduced CANMAB™ - Trastuzumab for Treating Breast Cancer in India

Syngene, a subsidiary of Biocon Group, in collaboration with Baxter sets up a dedicated Research and Development Center at Biocon Park

Silver Leaf Oak (Mauritius) Limited, an investment vehicle advised by India Value Fund Advisors has agreed to acquire a minority 10% stake in Syngene International Limited, Biocon's Research Services subsidiary. Silver Leaf will acquire the stake from Biocon Research Limited, a wholly owned subsidiary of Biocon Limited at a valuation of Rs.3800 Crore

Biocon Expands its Strategic Partnership with CytoSorbents for CytoSorb® to Treat SIRS and Cardiac Surgery Patients

2015

Biocon commissions Asia's largest integrated insulins manufacturing facility at the Biotech Park in Johor, Malaysia

Biocon Foundation Recognized for Outstanding Contribution to Public Health by WHO -India

Biocon Strengthens its Presence in Mexico; Receives Approval for Insulin Glargine through its partner PiSA Farmaceutica

Biocon's CRO Arm Syngene Seeks Approval for IPO, Files DRHP; Offer allows Biocon to monetize its shareholding in Syngene

Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed

Biocon's Biosimilars Programs Make Progress; One of the Largest

Generic Insulin Analogs and Biosimilars Portfolio in Advanced Stages of Development

Biocon's CRO Arm Syngene Lists on BSE and NSE; Valued at \$1 billion on Market Debut

Biocon Inaugurates World Class Devices Facility in Bangalore & Introduces Basalog One™ in India

Biocon is the Only Asian Company to be Ranked Among Top 20 Global Biotech Employers for 2015

2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Biocon Features in Asia IP Elite 2016 List

Biocon's Novel Diabetes Education Initiative for Medical Practitioners 'ABIDE' Awarded by RSSDI

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency

Biocon Ranked Among Global Top Ten Biotech Employers; The only Asian Company to Feature in 2016 Rankings

Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Biocon's Insulin Glargine Launched in Japan

Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting

Biocon Announced Data from Key Studies for Insulin Tregopil

Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY17

Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA

Biocon's Insulin Glargine Receives Regulatory Approval in Japan

2017

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Biocon started commercial operations at its Malaysia facility with the MYR 300 Million Contract from MoH, Malaysia to supply rh-insulin

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

Biosimilar Bevacizumab launched as KRABEVA® for patients of various types of cancer in India

U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) votes unanimously (16-0) for the approval of our biosimilar Trastuzumab

in July 2017

Biocon and partner Mylan became the first companies globally to receive U.S. FDA approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) is the first biosimilar from Mylan and Biocon's joint portfolio approved in the U.S.

Biocon is the first Indian company to receive a U.S. FDA approval for a biosimilar

2018

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommends for approval the Insulin Glargine co-developed by Biocon and Mylan in January 2018

The European Commission approves the sale of biosimilar Insulin Glargine, Semglee™ 100 units/mL 3 mL prefilled disposable pen, in March 2018

Therapeutic Goods Administration, Australia approves biosimilar Insulin Glargine, Semglee™ 100 IU/mL 3 mL prefilled pen, for people with diabetes in Australia

The U.S. FDA approves Fulphila™, a biosimilar Pegfilgrastim co-developed by Biocon and Mylan, in June 2018

Fulphila™, co-developed by Biocon and Mylan, becomes the first biosimilar Pegfilgrastim launched in U.S.

Biocon is first Company from India to commercialize a biosimilar in the U.S.

2019

Ogivri, co-developed by Biocon and Mylan, is the **first biosimilar Trastuzumab** to be approved in **Canada** for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer.

Biocon Biologics set up to consolidate the development, manufacturing and commercialization operations for biosimilars under an independent entity, with its own dedicated management.

Bicara Therapeutics is incorporated as a wholly owned subsidiary of Biocon in Boston, U.S., to focus on developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology.

Ogivri, co-developed by Biocon and Mylan, is the **first biosimilar Trastuzumab to be approved and launched in Australia** for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer.

Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia

Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.

2020

Biocon Biologics approves a primary equity investment by True North, starting the value unlocking process for Biocon's biosimilars subsidiary.

Biocon

[Home](#)
[About Us](#)
[Investor Relations](#)
[Media Relations](#)
[Careers](#)
[Site Map](#)
[Contact Us](#)

Businesses

[Our Growth Accelerators](#)
[Fact Sheet](#)
[Branded Formulations](#)
[Biopharmaceuticals](#)
[Research Services](#)
[Active Discovery Program](#)

Recommended sites

[ABLE](#)
[Karnataka Vision Group on BT](#)
[Syngene International](#)
[Biocon Academy](#)

Biocon on



Report adverse event/side effects and product complaints

* Disclaimer

© 2018, Biocon. All Rights Res